Company news
PegBio Co., Ltd. news
Latest news releases, newest first.
Form of proxy for use at the 2026 first extraordinary general meeting to be held on Thursday, November 12, 2026
October 23, 2026
Notice of the 2026 first extraordinary general meeting
October 23, 2026
(1) Proposed removal of auditor (2) proposed appointment of auditor (3) proposed change in use of proceeds from the global offering and (4) notice of the 2026 first extraordinary general meeting
October 23, 2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
October 7, 2026
2026 Interim Report
September 23, 2026
Change in use of proceeds from the global offering
September 18, 2026
Proposed change of auditor
September 18, 2026
Voluntary announcement core product Visepegenatide injection passed the preliminary review in accordance with the 2026 national reimbursement drug list adjustment
June 29, 2026
Next Day Disclosure Return
June 26, 2026
List of directors and their roles and functions
June 24, 2026